Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
12,772 people get MRK articles and Market Currents by email alert.
Get email alerts on MRK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Merck's Liptruzet: A Cause For Shame?Derek Lowe • Thu, May 9 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Merck & Co.'s CEO Discusses Q1 2012 Results - Earnings Call TranscriptFri, Apr 27, 2012
-
Merck & Co. Inc. - Special CallThu, Nov 10, 2011
-
Merck & Co.'s CEO Discusses Q3 2011 Results - Earnings Call TranscriptFri, Oct 28, 2011
-
Merck & Co.'s CEO Discusses Q2 2011 Results - Earnings Call TranscriptFri, Jul 29, 2011
-
Merck & Co.'s CEO Discusses Q1 2011 Results - Earnings Call TranscriptFri, Apr 29, 2011
-
Merck CEO Discusses Q3 2010 Results - Earnings Call TranscriptFri, Oct 29, 2010
-
Merck & Co. Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Merck & Co. Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Merck & Co., Inc. Q4 2009 Earnings Call TranscriptTue, Feb 16, 2010
-
Merck & Co., Inc. Q3 2009 Earnings Call TranscriptThu, Oct 22, 2009
-
Merck & Co. Inc. Q2 2009 Earnings Call TranscriptTue, Jul 21, 2009
-
Merck F1Q09 Earnings Call TranscriptTue, Apr 21, 2009
-
at CNBC.com (Wed, 4:08PM)
-
at CNBC.com (Wed, 9:57AM)
-
at CNBC.com (Wed, 8:06AM)
-
at MarketWatch.com (Tue, 4:59PM)
-
at CNBC.com (Tue, 4:51PM)
-
at MarketWatch.com (Tue, 4:37PM)
-
at CNBC.com (Tue, 4:07PM)
-
at CNBC.com (Mon, 6:26PM)
-
at MarketWatch.com (Mon, 4:38PM)
-
at CNBC.com (Fri, 1:43PM)
-
Business Wire (May 15, 2013)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 2, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at Fox Business (May 1, 2013)
MRK vs. ETF Alternatives
Company Description
On November 3, 2009, Merck & Co., Inc. (“Old Merck”) and Schering-Plough Corporation (“Schering-Plough”) completed their previously-announced merger (the “Merger”). In the Merger, Schering-Plough acquired all of the shares of Old Merck, which became a wholly-owned subsidiary of Schering-Plough... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, December 31, 2012, 9:00 AM Not all diagnostics companies are worried at the prospect of the Supreme Court striking down patents on two cancer-related genes "owned" by Myriad (MYGN) in a decision that is due to come in 2013. Quest (DGX) says it could be a "positive development," as it would "open new opportunities to develop new testing services." Myriad, which has spent 17 years and $500M on isolating the "DNA molecules and processes," isn't so sanguine. Comment! [Healthcare]
- Thursday, December 20, 2012, 9:00 AM Merck's (MRK -2.9%) Tredaptive (Cordaptive) cholesterol treatment failed to meet its primary goal in a massive study of 25,673 patients. The drug didn't significantly cut the risk of coronary deaths, non-fatal heart attacks, strokes or revascularizations compared with statin therapy. Merck will end its bid to for regulatory approval of Tredaptive in the U.S.; the drug is sold in 40 countries and had sales of $13M in Q1-Q3. (PR) 1 Comment [Healthcare]
- Tuesday, December 18, 2012, 6:15 PM The top 10 dividend-yielding stocks from the "ultimate stock pickers" at Morningstar: GSK, COP, INTC, LLY, NVS, MRK, PM, PFE, SYY, JNJ. 14 Comments [Quick Ideas]
- Tuesday, December 18, 2012, 8:39 AM Merck (MRK) signs a deal to use GE Healthcare's (GE) Flutemetamol imaging agent in clinical studies of Merck's MK-8931 drug for treating Alzheimer's disease. Flutemetamol, which performed well in its own Phase III trials, helps detect beta amyloid deposits in the brain. The build-up of beta amyloid has been associated with Alzheimer's. (PR) Comment! [Healthcare]
- Thursday, December 13, 2012, 7:18 PM Merck (MRK) receives FDA approval to revise the biologics labeling on both the refrigerator-stable and frozen formulations of it's Chicken pox vaccine Varivax Details of the revised labeling aren't currently available. Comment! [Healthcare]
- Thursday, December 13, 2012, 8:22 AM Merck (MRK) CEO Kenneth Frazier jostles for positioning in the fiscal cliff debate, warning that proposals to put "additional price controls on drugs" could "take away much of the incentive in the capital markets to invest in research and development." The Democrats have proposed reducing soaring medical costs by using Medicare to negotiate lower drug prices. Comment! [Healthcare]
- Tuesday, December 11, 2012, 6:48 PM Goldman Sachs (GS) gets the nod by Warburg Pincus to explore a sale of Bausch & Lomb, the company's eye-care division. Warburg is said to be seeking at least $10B for the business. According to reports, Goldman has already contacted Sanofi (SNY), GlaxoSmithKline (GSK), and Merck (MRK) this month, and that Abbott Laboratories (ABT) will be among the other companies contacted. Comment! [Healthcare, M&A]
- Tuesday, December 11, 2012, 10:48 AM Cardiome Pharma (CRME +41%) leaps higher out of an earlier trading halt after the company says it's reached a deal with Merck (MRK +0.6%) to settle its debt obligations stemming from it's collaboration on vernakalant - a treatment for atrial fibrillation - which it signed in April 2009. Under the terms of the settlement, CRME will pay MRK $20M to settle its outstanding debt of $50M, and MRK will terminate a $100M credit facility it had made available to CRME. Comment! [Healthcare, On the Move]
- Tuesday, December 11, 2012, 8:53 AM India revokes yet another pharmaceutical patent owned by a foreign multinational, with Merck (MRK) losing protection for an asthma treatment after domestic drug-maker Cipla challenged an earlier decision. Pfizer, Roche and Novartis are among those to have experienced patent trouble in the country. (previous) 1 Comment [Healthcare]
- Sunday, December 9, 2012, 2:27 AM The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous) 1 Comment [Healthcare, Top Stories]
- Friday, December 7, 2012, 4:41 AM The Supreme Court could say today whether it will review a case involving a "pay for delay" agreement in which a pharmaceutical company pays generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation. Companies that could be affected include Abbott (ABT), Watson (WPI), Merck (MRK), Bristol-Myers Squibb (BMY) and Teva (TEVA). Comment! [Healthcare, Top Stories]
- Tuesday, December 4, 2012, 8:13 AM An appeals court ruling yesterday that dismissed the conviction of a sales rep who sold a drug for non-FDA approved uses could have major ramifications for pharmaceutical companies, which have paid billions in fines for doing just that. Two out of three judges agreed with Alfred Caronia that his rights to free speech were violated. The government is expected to appeal the case, which could find its way to the Supreme Court. 9 Comments
- Monday, December 3, 2012, 2:13 PM Merck's (MRK +0.4%) MK-8931 Alzheimer's drug has entered Phase II trials, the company announces. The drug attempts to prevent a worsening of Alzheimer's by blocking production of a protein believed to contribute to the disease. Eli Lilly (LLY) has reported positive Phase III trial results for its solanezumab Alzheimer's drug, when administered to patients with mild symptoms. Comment! [Healthcare]
- Wednesday, November 28, 2012, 5:56 AM Numerous CEOs of major companies are off to Washington today to talk to President Obama and/or John Boehner about averting the fiscal cliff. Those meeting Obama include the leaders of Merck (MRK), Coca-Cola (KO) and Caterpillar (CAT), while those meeting Boehner include the CEOs of Honeywell (HON) and Aetna (AET). Company bosses have also been urging their staff to pressure Washington to reach a deal. 3 Comments [U.S. Economy]
- Tuesday, November 27, 2012, 3:29 PM Merck (MRK) declares $0.43/share quarterly dividend, 2.38% increase from prior dividend of $0.42. Forward yield 3.89%. For shareholders of record Dec 17. Payable Jan 08. Ex-div date Dec 13. (PR) Comment! [Dividends]
- Tuesday, November 27, 2012, 10:16 AM Novo Nordisk's (NVO -0.2%) Victoza's outperformed Merck's (MRK -0.2%) Januvia and Amylin's (BMY) exenatid BID in patients with type two diabetes. More subjects given Victoza had a blood-sugar level below 7% those who received the rival drugs. (PR) 1 Comment [Healthcare]
-
The Wall Street Transcript
Merck ($MRK), Vertex Pharmaceuticals ($VRTX) and Gilead Sciences ($GILD) Trailblaze Hepatitis C Therapies - http://su.pr/2L7YFf - View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them - View all 1 replies
-
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
-
- View all 0 replies
-
- View all 0 replies
-
David Crosetti
It's a beautiful day in the neighborhood! Great rally! Rebalancing the portfolio today! Hot dog! MRK up 4%?? Wow. - View all 6 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES